PainChek, an artificial intelligence (AI)-powered pain assessment tool, has reported sustained growth in market traction as well as 400% growth in its UK team, just two years since its launch in the UK.
The company, which started out in Australia, has 8,500 beds in UK residential care homes now using the PainChek technology, over 1,300,000 pain assessments worldwide, and reports sustained growth in demand from UK care providers.
A medical device for use on mobile phones and tablets, PainChek uses AI (facial detection and analysis technology) and smart automation to detect and score pain in real time. The tool has regulatory clearance as a medical device in the UK, Australia, Canada, the EU, and New Zealand.
The company’s Tandeep Gill says PainChek is well positioned to continue its growth momentum in the UK: “Through government-funded pilots, integrations with eMAR and care planning partners, and a vision to move into new markets, our growth strategy is very much on track .
“Our ongoing expansion in the UK is a core part of PainChek’s plans for this year. We have recorded a surge in interest, enquiries, and uptake of PainChek from a range of care providers, from those with well-established digital systems as well as those looking to make the first entry into their digital journey. Indeed, with the UK government’s digitization target front of mind, many care providers are realizing the value, time and cost savings digital tools can bring.
“Worldwide, cases of people living with dementia are predicted to treble to 153 million by 2050. Timely detection and management of pain is integral to ensuring high quality care and quality of life for care home residents living with dementia, and this starts with accurate pain assessment for those unable to self-report their pain.”
PainChek has successfully supported pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions which impact their ability to reliably self-report pain. Building on this success and technology, the recently validated, world-first PainChek Infant app has been developed to ensure pain can also be identified in pre-verbal children aged one month to 12 months who have yet to learn to self-report their pain.
The Infant app has received regulatory clearance in the UK, Australia, Europe, Canada, and New Zealand, and will soon be available for use by UK healthcare professionals in settings including clinical studies, hospitals, and GP clinics.